Stock PAR PARADIGM BIOPHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Paradigm Biopharmaceuticals Limited

Equities

PAR

AU000000PAR5

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:46 2024-04-30 am EDT 		5-day change 1st Jan Change
0.27 AUD +5.88% Intraday chart for Paradigm Biopharmaceuticals Limited -5.26% -36.47%
Apr. 19 Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program MT
Feb. 28 Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Valuation

Fiscal Period: Junio 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 269.1 708 482.8 224.2 278.9 94.6 - -
Enterprise Value (EV) 1 269.1 604.2 412.5 224.2 278.9 94.6 94.6 94.6
P/E ratio -12.8 x -51.5 x -12.5 x -5.72 x -4.76 x -1.51 x 6.92 x 2.43 x
Yield - - - - - - - -
Capitalization / Revenue 82,908,610 x 150,773,056 x 53,994,726 x 2,829,779,033 x 5,965,328,828 x - - -
EV / Revenue 82,908,610 x 150,773,034 x 53,994,718 x 2,829,779,033 x 5,965,328,828 x - - -
EV / EBITDA -31 x -58.7 x -14.2 x -5.74 x -5.39 x -1.8 x 7.63 x 2.61 x
EV / FCF -42.2 x -69.3 x -13.8 x -6.96 x -6.17 x -1.82 x 7.33 x 2.17 x
FCF Yield -2.37% -1.44% -7.24% -14.4% -16.2% -55% 13.6% 46%
Price to Book 3.25 x 6.54 x 6.17 x 5.31 x 5.2 x 45 x 2.25 x 1.15 x
Nbr of stocks (in thousands) 192,208 224,747 229,906 232,306 281,757 350,364 - -
Reference price 2 1.400 3.150 2.100 0.9650 0.9900 0.2700 0.2700 0.2700
Announcement Date 8/30/19 8/27/20 8/26/21 8/25/22 8/25/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 3.246 4.695 8.942 0.0792 0.0468 - - -
EBITDA 1 -8.69 -12.05 -34.05 -39.03 -51.74 -52.5 12.4 36.2
EBIT 1 -8.699 -12.26 -34.26 -39.22 -51.89 -52.5 12.4 36.2
Operating Margin -268.01% -261.2% -383.14% -49,508.9% -110,978.61% - - -
Earnings before Tax (EBT) 1 -15.63 -12.3 -34.3 -39.25 -51.91 -52 12.9 36.7
Net income 1 -15.63 -12.3 -34.3 -39.25 -51.91 -52 12.9 36.7
Net margin -481.49% -261.93% -383.57% -49,545.04% -111,013.71% - - -
EPS 2 -0.1093 -0.0612 -0.1674 -0.1687 -0.2078 -0.1790 0.0390 0.1110
Free Cash Flow 1 -6.383 -10.22 -34.96 -32.21 -45.19 -52 12.9 43.5
FCF margin -196.66% -217.6% -390.98% -40,652.95% -96,634.47% - - -
FCF Conversion (EBITDA) - - - - - - 104.03% 120.17%
FCF Conversion (Net income) - - - - - - 100% 118.53%
Dividend per Share - - - - - - - -
Announcement Date 8/30/19 8/27/20 8/26/21 8/25/22 8/25/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: Juni 2021 S1 2021 S2 2022 S1 2022 S2
Net sales - - - -
EBITDA - -13.44 - -
EBIT 1 - -13.55 - -12.25
Operating Margin - - - -
Earnings before Tax (EBT) - - - -
Net income -20.73 - -26.99 -
Net margin - - - -
EPS -0.0910 - -0.1180 -
Dividend per Share - - - -
Announcement Date 2/24/21 8/26/21 2/23/22 8/25/22
1AUD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - 104 70.3 - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -6.38 -10.2 -35 -32.2 -45.2 -52 12.9 43.5
ROE (net income / shareholders' equity) -10.5% -15.5% -36.8% - - - 6.4% 24.3%
ROA (Net income/ Total Assets) - -16.1% - - - - - -
Assets 1 - 76.44 - - - - - -
Book Value Per Share 2 0.4300 0.4800 0.3400 0.1800 0.1900 0.0100 0.1200 0.2300
Cash Flow per Share - -0 -0.1700 - -0.1600 - - -
Capex - 0.13 0.03 - - - - -
Capex / Sales - 2.79% 0.34% - - - - -
Announcement Date 8/30/19 8/27/20 8/26/21 8/25/22 8/25/23 - - -
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.27 AUD
Average target price
2.295 AUD
Spread / Average Target
+750.00%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PARADIGM BIOPHARMACEUTICALS LIMITED Stock Paradigm Biopharmaceuticals Limited
-36.47% 58.6M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.86B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.74B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PAR Stock
  4. Financials Paradigm Biopharmaceuticals Limited